WEKO3
アイテム
Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin
https://dmu.repo.nii.ac.jp/records/1235
https://dmu.repo.nii.ac.jp/records/1235b1b95a02-34c9-4334-93fb-40a4a6639e8a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00009545199.pdf (130.8 kB)
|
|
| Item type | [ELS]学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-05-24 | |||||
| タイトル | ||||||
| タイトル | Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Type 2 Diabetes | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Glucagon-like Peptide-1 Receptor Agonist | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Liraglutide | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Dipeptidyl Peptidase-4( Dpp-4) Inhibitors | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Flow-mediated Dilatation | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 雑誌書誌ID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00629581 | |||||
| 論文名よみ | ||||||
| タイトル | Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin | |||||
| 著者 |
Suzuki, Kunihiro
× Suzuki, Kunihiro× Tanaka, Seiichi× Aoki, Chie× Kato, Kanako× Jojima, Teruo× Aso, Yoshimasa |
|||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 著者所属(英) | ||||||
| 言語 | en | |||||
| 値 | Department Of Endocrinology And Metabolism, Dokkyo Medical University School Of Medicine | |||||
| 記事種別(英) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Original | |||||
| 抄録(英) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Objective:The incretin hormone glucagon-like peptide 1 (GLP-1) and its analogs, including the glucagonlike peptide 1 receptor agonist liraglutide, use a simple once-daily regimen and can be easily introduced in the outpatient setting. We compared treatment with liraglutide monotherapy and dipeptidyl peptidase-4 (DPP-4) inhibitor monotherapy in patients with untreated type 2 diabetes( T2DM).Methods:This study included 40 outpatients with untreated T2DM who were randomized to receive liraglutide (0.9 mg/day, n=24) or DPP-4 inhibitors (n=16:sitagliptin, 50 mg/day) as initial treatment for 6 months. Glycemic control, urinalysis, blood pressure, body weight, lipid levels, vascular endothelial function, and inflammatory factors were assessed before and after treatment.Results:Significant improvement was observed in HbA1c and fasting blood glucose levels after treatment in both groups;improvements in the liraglutide group were significantly better than in the sitagliptin group. Only the liraglutide group demonstrated significant improvements in blood pressure, low-density lipoprotein cholesterol levels, urinary albumin excretion, flow-mediated dilatation, and high-sensitivity C-reactive protein levels. Linear regression analysis demonstrated a significant negative relation between change in flow-mediated dilatation and high-sensitivity C-reactive protein levels.Conclusion:Liraglutide provided significant glycemic control and improved blood pressure, lipid levels, endothelial function, and inflammatory factors in untreated T2DM. In addition to its impact on blood glucose levels, liraglutide may have beneficial effects on the cardiovascular system in patients with T2DM. | |||||
| 書誌情報 |
Dokkyo journal of medical sciences 巻 41, 号 3, p. 211-220, 発行日 2014-10-25 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 03855023 | |||||
